Journey Medical Q2 revenue rises 23% to $18.5 million on Emrosi sales growth
DERM•Profitability and balance sheet
- GAAP net loss narrowed to $312,000 from $3.8 million a year earlier.
- Gross margin held at 67%.
- Cash and cash equivalents totaled $25.6 million at June 30, 2026, up from $24.1 million at year-end 2025.
Q2 revenue growth and Emrosi sales
- Fortress Biotech unit Journey Medical posted Q2 2026 revenue of $18.5 million, up 23% year over year.
- Emrosi revenue reached $8.1 million; total prescriptions rose to about 36,000 from about 30,000 in Q1 2026.
Related News
Sphere Entertainment FY26 net income rises 77% to $66.19 million; revenue climbs 13% to $1.06 billion
SPHR•
Interprivate Investment Partners V posts Q2 FY26 net income of $315,745
IPVV•
